Saturday, 31 October 2026European Markets

SIPEF, JACQUES BOGART, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - sipef (sip.br) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
sipef (sip.br) €53.80 3.91% 8.78%
jacques bogart (jbog.pa) €6.70 3.06% 7.12%
savencia (save.pa) €51.20 2.83% 5.81%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. sipef (sip.br)

3.91% forward dividend yield and 8.78% return on equity

sipef nv operates as an agro-industrial company. the company operates through palm, rubber, tea, and bananas and horticulture segments. it also offers crude palm oil, palm kernels, and palm kernel oil ; ribbed smoked sheets, and scraps and lumps; cut, tear, and curl tea; flowers, foliage, and bananas. the company operates in papua new guinea, ivory coast, singapore, europe, indonesia, and internationally. sipef nv was incorporated in 1919 and is headquartered in schoten, belgium.

earnings per share

as for profitability, sipef has a trailing twelve months eps of €5.8.

pe ratio

sipef has a trailing twelve months price to earnings ratio of 9.28. meaning, the purchaser of the share is investing €9.28 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.78%.

yearly top and bottom value

sipef's stock is valued at €53.80 at 17:30 est, below its 52-week high of €58.80 and way higher than its 52-week low of €48.40.

moving average

sipef's worth is under its 50-day moving average of €54.56 and higher than its 200-day moving average of €53.71.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, sipef's stock is considered to be oversold (<=20).

volume

today's last reported volume for sipef is 412 which is 74.28% below its average volume of 1602.

more news about sipef.

2. jacques bogart (jbog.pa)

3.06% forward dividend yield and 7.12% return on equity

jacques bogart s.a. produces and sells fragrances and cosmetics in paris and internationally. the company markets its fragrance products under the jacques bogart, carven, chevignon, and ted lapidus brand names; cosmetic products under the stendhal, methode jeanne piaubert, and april brand names; and fashion products under the ted lapidus fashion brand name. jacques bogart s.a. was founded in 1975 and is based in paris, france.

earnings per share

as for profitability, jacques bogart has a trailing twelve months eps of €-0.61.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.12%.

volume

today's last reported volume for jacques bogart is 984 which is 4.37% below its average volume of 1029.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, jacques bogart's stock is considered to be oversold (<=20).

dividend yield

as stated by morningstar, inc., the next dividend payment is on jul 3, 2024, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 3.06%.

volatility

jacques bogart's last week, last month's, and last quarter's current intraday variation average was 1.22%, 0.07%, and 2.30%.

jacques bogart's highest amplitude of average volatility was 3.88% (last week), 2.79% (last month), and 2.30% (last quarter).

more news about jacques bogart.

3. savencia (save.pa)

2.83% forward dividend yield and 5.81% return on equity

savencia sa produces, distributes, and markets dairy and cheese products in france, rest of europe, and internationally. it offers cheese, butters, creams, and dairy ingredients and nutritional solutions for the retail market and foodservices market. the company provides its products under the caprice des dieux, saint albray, le rustique, cœur de lion, saint agur, bresse bleu, pdo roquefort papillon, st-morêt, tartare, carré frais, apérivrais, chavroux, saint-loup, richesmonts raclette, géramont, saint albray, fol epi, bresso, milkana, brunch, burgo de arias, ile de france, milkaut, santa rosa, delaco, kral syru, lucina, král sýru, medve, alouette, rogue creamery, polenghi, corman, balade, and elle & vire brands. the company was formerly known as bongrain sa and changed its name to savencia sa in april 2015.savencia sa was founded in 1956 and is headquartered in viroflay, france. savencia sa operates as a subsidiary of savencia holding.

earnings per share

as for profitability, savencia has a trailing twelve months eps of €7.21.

pe ratio

savencia has a trailing twelve months price to earnings ratio of 7.1. meaning, the purchaser of the share is investing €7.1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.81%.

yearly top and bottom value

savencia's stock is valued at €51.20 at 17:30 est, below its 52-week high of €56.60 and higher than its 52-week low of €48.20.

moving average

savencia's value is under its 50-day moving average of €51.24 and below its 200-day moving average of €52.67.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, savencia's stock is considered to be oversold (<=20).

more news about savencia.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com